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ABSTRACT
Introduction: Vancomycin remains one of our
essential antibiotics after fifty years of treating
serious infections such as methicillin-resistant
Staphylococcus aureus. Vancomycin, unlike
many other antibiotic agents, requires individ-
ualized dosing and monitoring of serum drug
levels to ensure it is efficacious, to minimize
toxicity, and to limit the development of
antibiotic resistance. These issues have led to
numerous vancomycin clinical practice guide-
lines being published in recent years including
several key national guidelines. Significant
resources are invested during the development
of such guidelines; however, there is often little
or no information about how such guidelines or
other vancomycin practice improvement ini-
tiatives should be implemented. The aim of this
systematic review is to identify and evaluate the
effect of interventions using education, guide-
line implementation, and dissemination of
educational resources that have sought to
improve therapeutic drug monitoring and dos-
ing of vancomycin.
Methods: A systematic review of the literature
will be conducted for RCTs and observational
studies where a vancomycin guideline or
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practice improvement initiative has been
implemented. Electronic databases to be sear-
ched are PubMed, Medline, CINAHL, EMBASE
and the Cochrane Library of Systematic
Reviews. The population will be patients who
have had intravenous vancomycin prescribed
and monitored in hospital. The interventions
will be education, implementation of guidelines
or protocols, dissemination of educational
materials (printed or electronic) or multifaceted
interventions of the above. The comparator will
be patients who have had standard-care pre-
scribing and monitoring of vancomycin. Out-
comes will be changes in prescribing and
ordering of vancomycin serum tests, and serum
levels attained in patients as well as reported
nephrotoxicity. Two reviewers will be involved
in the quality assessment and extraction of
data. The Scottish Intercollegiate Guidelines
Network checklist for RCTs will be used. Studies
that are not randomized will be assessed for
quality using the validated ROBINS-I (risk of
bias in non-randomized studies of interven-
tions) tool.
Discussion: This systematic review will identify
interventions that have been used to imple-
ment guidelines and clinical practice initiatives
for vancomycin. The findings of this review
may be informative to those involved with the
implementation of vancomycin clinical prac-
tice guidelines.
Systematic review registration: PROSPERO:
CRD42016049147.
Keywords: Education; Guideline; Implemen-
tation; Intervention; Protocol; Vancomycin
INTRODUCTION
While vancomycin has been used for nearly
60 years, it remains the principal treatment for
infection caused by serious Gram-positive bac-
teria such as methicillin-resistant Staphylococcus
aureus (MRSA) [1]. Vancomycin, unlike many
other antibiotics, has a number of special con-
siderations, such as the requirement for individ-
ualization of dosing and serum drug monitoring
to ensure efficacy, minimize toxicity and limit
the development of bacterial resistance [2–4].
These factors, in addition to increasing concerns
about antimicrobial resistance [5, 6] and theneed
to prolong the life of our existing antibiotics,
have led to the publication of a number of van-
comycin guidelines [7], including important
national guidelines for the dosing and or moni-
toring of vancomycin from the United States
(US), Japan and China [8–10]. Significant effort
and resources are invested in the process and
preparation of such high-quality national
guidelines, which are endorsed by peak profes-
sional societies in their respective countries
[11, 12]. These documents providemuch needed
contemporary guidance on the appropriate use
of vancomycin; however, there is a paucity of
information about how these vancomycin
guidelines and their contents should be best
disseminated and implemented into practice to
achieve the intendedoutcomes for clinicians and
patients. Only one guideline, by the Chinese
Pharmacological Society [10], includes some
information about implementation. The imple-
mentation details associated with this guideline
propose promotion via conferences, education
sessions for physicians, pharmacists and nurses,
and research to evaluate both the implementa-
tion and impact of the guideline on vancomycin
therapeutic drug monitoring (TDM) [13].
There are numerous reports in the medical
literature that highlight clinicians lack of
knowledge of the contents of key guidelines in
addition to an often low uptake of guidelines
[14–16]. To combat this issue, adoption strate-
gies have been recommended by a number of
prominent organizational developers of guide-
lines such as the Australian National Health
and Medical Research Council (NHMRC)
[17, 18], the United Kingdom’s National Insti-
tute for Health and Clinical Excellence (NICE)
[19], the Scottish Intercollegiate Guideline
Network (SIGN) [20], and the US Institute of
Medicine (IOM) [21]. While it is prudent that
any plan to implement a guideline or practice
change should include an assessment of the
barriers and enablers [22], there are common
implementation strategies recommended by
these organizations, which are widely
employed. Such strategies include the provi-
sion of education about the guideline and its
recommendations [23]. Educational meetings
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have demonstrated changes in practice mea-
sures between 1.8% and 15.9% [24], while dis-
semination of guidelines and educational
supporting material have been shown to have a
median 8.1% improvement on care [25],
although there have been recent concerns
about the effectiveness of the latter [26].
Determination of the relative effectiveness of
these strategies to promote the implementation
of guidelines or practice change initiatives for
vancomycin is important to prudently allocate
supportive resources. While a systematic review
on guidelines for TDM of vancomycin has been
published [7], the current review aims to
identify and evaluate the effect of interventions
employing education, guideline implementa-
tion and dissemination of educational resour-
ces on the therapeutic drug monitoring and
dosing of vancomycin.
METHODS
The steps of the systematic review to be con-
ducted will be defining the inclusion criteria
and exclusion criteria, searching for and cap-
turing studies, and identifying studies that
address the review question and are in accor-
dance with the criteria. Defined data will be
extracted and compiled. This systematic review
protocol will follow the Preferred Reporting
Items for Systematic Review and Meta-Analysis
Protocols (PRISMA-P) 2015 statement [27, 28].
The PRISMA-P 2015 checklist for this review
accompanies this protocol as Supplementary
material 1.
Research Question
This review aims to systematically identify and
determine the effect of interventions that have
targeted the therapeutic drug monitoring and
dosing of the intravenous antibiotic van-
comycin.. The specific review question is:
Do interventions (alone or in combination)
involving; education, implementation of
guidelines or protocols, or dissemination of
educational materials (printed or electronic)




The review populations, interventions, com-
parator group and outcomes [29], to be assessed
in the systematic review are presented in
Table 1.
Selection of Studies and Inclusion/
Exclusion Criteria
A preliminary search suggests that there are
limited RCTs on this topic, so observational,
including before–after studies and interrupted
time series studies, will also be included in
addition to RCTs. The review will include
studies that have employed documented
implementation strategies for vancomycin
guidelines and protocols, educational interven-
tions (face-to-face or electronic, disseminations
of educational materials (printed or electronic)
or multifaceted strategies using a combination
of these. Studies to be excluded will be those
using population pharmacokinetic modeling of
guidelines or protocols, those comparing one
explicit guideline directly against another (e.g.,
continuous versus intermittent dosing), those
with no comparison to control or baseline data,
and those where the post-implementation
assessment excluded patients who were not
dosed in accordance with the new guideline (as
this may bias and misrepresent uptake of the
guideline). Studies will also be excluded if they
focus solely on indication for vancomycin or
duration of usage. Studies involving oral van-
comycin for Clostridium difficile infection will be
excluded as this therapy does not involve TDM.
Search Strategy and Data Storage
The search strategy was developed in collabo-
ration with an academic medical librarian
experienced in conducting searches for system-
atic reviews. Search strategies will employ
medical subject headings (MeSH) [30], and key
words pertaining to the research question. The
electronic database search was initially devel-
oped for Ovid MEDLINE (full search strategy
presented as Supplementary material 2). The
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search strategy was then adapted for PubMed,
EMBASE (Excerpta Medica Database), CINAHL
(Cumulative Index to Nursing and Allied Health
Literature) and the Cochrane Library of Sys-
tematic Reviews. The search will be filtered to
capture articles in the English language only. As
vancomycin was first licensed with the US Food
and Drug Administration in the 1950s, the
search strategy will span all articles in the
respective databases from inception. To further
the search strategy, any relevant studies identi-
fied by members of the review team will be
captured. The search will be re-performed prior
to closing the review to ensure any recently
published articles are captured. Publications will
be stored in in a dedicated electronic library
using EndNote X7.7 referencing software
(Thompson Reuters, 2016), with duplicate ref-
erences to be removed. Data collection will be
performed using Microsoft Excel (Microsoft,
2017).
Data Analysis and Synthesis
The preliminary screening of captured articles
will be performed to determine if the titles or
abstracts address the review question. A second
reviewer will independently review articles to
determine if they are in agreement with the
suitability of selected articles. Any differences
will be resolved through discussion with a third
member of the review team. The following stage
will be accessing full text articles to determine
eligibility for final inclusion, when a second
reviewer will independently check that they
agree with the identified articles. Any disagree-
ment will be resolved by a third member of the
review team. An assessment of the quality of
articles will be performed. The SIGN checklist
for RCTs will be used [20]. Studies that are not
randomized will be assessed using the validated
tool ROBINS-I (Risk of bias in non-randomized
studies of interventions) [31].
Data variables to be collected are study
demographics, authors, year, country, care set-
ting (unit or ward) in hospital, type of study,
intervention type and description of interven-
tion, intended effect of intervention, use of any
theory for the intervention, learning objectives,
materials used, educational strategies, schedule,
instructions and modes used, use of incentives
and environment [32]. Data for outcomes will
be authors’ results for vancomycin prescribing,
drug monitoring and nephrotoxicity. This arti-
cle does not contain any new studies with
human or animal subjects performed by any of
the authors.
DISCUSSION
Studies have demonstrated hospital doctors do
not prescribe antibiotics appropriately nearly
half of the time [33], and one-quarter of hospi-
tals in Australia have been reported as non-ad-
herent to guidelines [34]. Determination of the
Table 1 PICO framework
Population Patients who have had vancomycin prescribed and monitored in hospital
Interventions Education, implementation of guidelines or protocols, or dissemination of educational materials (printed or
electronic) or multifaceted interventions of the above
Comparators Standard care prescribing and monitoring of vancomycin
Outcomes Prescribing The proportion of patients prescribed loading doses, and prescribed maintenance doses
appropriate for renal function
Monitoring The proportion of vancomycin blood levels drawn at appropriate times, attaining specified target
ranges, and in levels outside specified ranges
Safety Frequency of reported nephrotoxicity (increase in serum creatinine of 0.5 mg/dL or[50% from
baseline on C 2 or more consecutive measurements) after 2 or more days of vancomycin [8]
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strategies that promote effective implementa-
tion should be a fundamental component of
guideline development and practice improve-
ment initiatives. The published literature on
vancomycin prescribing and monitoring shows
that there is considerable room for improvement
for this half-century-old antibiotic. The findings
from this systematic review will be summarized
in tabular format providing ready interpretation
and comparison of studies. We will provide a
narrative synthesis of the findings from included
studies structured around the type of interven-
tion, prescriber and population characteristics
and outcomes. We will also discuss the strengths
and limitations of included studies. We elected
not to measure clinical efficacy or microbiolog-
ical outcomes, as we wanted to focus on out-
comes pertaining specifically to dosing, TDM
and toxicity which are highly appropriate as
these are directly related to interventions pro-
viding guidance, education or dissemination of
resources seeking to improve vancomycin dos-
ing and TDM and to limit toxicity. This review
will be informative in providing guidance on
how successful the examined interventions are
in effecting appropriate prescribing and moni-
toring of vancomycin. The findings of this
review will help those seeking to improve the
clinical use of vancomycin by selecting effective
interventions to implement guidelines or other
practice improvement initiatives.
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